Authors:

Margaret Doucette and Stephanie Seabolt

Margaret Doucette is Associate Chief of Staff for Research at Boise VA Medical Center and Medical Director for the Wound/High Risk Foot/ Amputee Program. Clinical Associate Professor Univ of Washington, US;

Stephanie Seabright is Registered Nurse Clinical Research Coordinator at the Boise VA Medical Center working in wound/high risk foot clinic and Masters of Science in Nursing graduate student at Western Governor’s University, US Am putation of a lower extremity can be devastating, debilitating and demoralising, or it can be a successful, beneficial, definitive end point to a nonhealing diabetic foot ulcer (DFU). The decisionmaking process of if, and when, to amputate begins at the first patient visit and should be incorporated into the patient discussion early on for all high-risk patients. While prevention of amputation is most commonly the goal, early identification of risk factors and risk stratification can help design a realistic care plan, compassionately inform patient expectations and steward resource allocation. These 10 top tips will help guide you with the plan of care.

Chronic wounds are becoming of public health concern, and despite extensive literature supporting the use of electrotherapy in the management of chronic wounds, Nigerian physiotherapists are rarely involved in wound care. This study sought to determine physiotherapists’ knowledge and use of electrotherapy in wound management. It used a self-administered questionnaire to collect information from physiotherapists in various practice settings. It was found that the majority of respondents (98.7%) had a good understanding of the role of electrotherapy in wound care, but had a poor understanding of both precaution (10.2%) and wound assessment (7.9%). Only 11.8% of physiotherapists were found to be involved in wound care and there was no association between knowledge and job rank (P =0.27).

Author:

Chioma Lynn Onuchukwu

Chioma Lynn Onuchukwu is Chief Physiotherapist, Enugu State University Teaching Hospital, Enugu, Nigeria

      The treatment of diabetic foot infections (DFIs) represents a costly and growing challenge to the NHS. DFIs can be difficult to treat for a variety of reasons, including late presentation of advanced infection, and antibiotic tolerance or resistance. Bacteriophage (phage) are ubiquitous viruses that infect and kill bacteria in a species-, sometimes even strain-, specific manner. Phages have been used to treat bacterial infection since 1919, but their use in the geopolitical West ceased in the 1930s due to a variety of factors, including the mass production of antibiotics. The modern antibiotic resistance crisis has driven renewed interest in phage therapy and 2,241 patients with mostly with antibiotic refractory infections have been treated since 2000, 79% of whom improved. This includes at least 310 patients with chronic wound infections, among whom 86.1% achieved clinical resolution or improvement of infection. Reassuringly, the available evidence suggests that phage therapy is safe and without notable side effects. Some phages also possess enzymes capable of degrading the biofilms that afford antibiotic tolerance to bacteria and underpin many chronic infections. Phages also act independent of antibiotic resistance, allowing the treatment of even pan-resistant bacteria, and topical or local application to DFIs means antimicrobial activity is independent of a patient’s peripheral perfusion. Presently only an option when antibiotics are not meeting a patient’s clinical needs, future integration of phage therapy at all levels of DFI care will radically transform the outlook for DFIs in the UK. Reducing the number of serious infections and amputations will not only benefit patients but will deliver vast savings to the NHS and reduce the amount of antibiotics used, making phage therapy a tangible response to the antibiotic resistance crisis.

Authors:

Matthew J Young, Lesley ML Hall and Joshua D Jones

This article first appeared in our sister publication, The Diabetic Foot Journal, in the November 2022 issue. Citation: Young MJ, Hall LML, Jones JD (2022) Phage therapy for diabetic foot infection 25(4): 30–7

Matthew J. Young is Consultant Physician, Royal Infirmary of Edinburgh, Edinburgh, UK;

Lesley ML Hall is Consultant Physician, Diabetes and Endocrinology, Queen Elizabeth University Hospital, Glasgow, UK;

Joshua D Jones is Consultant Physician, Infection Medicine, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, UK; Clinical Microbiology, Ninewells Hospital, NHS Tayside, Dundee, UK

ABSTRACT: One of the most common questions asked to specialist healthcare professionals and educators in wound management is how to choose a suitable dressing. The importance of holistic assessment and diagnosis to accurately identify wound aetiology, the effect of comorbidities and associated risks for non-healing is paramount. This initial holistic assessment should be the starting point and given continued consideration throughout the wound healing process. In practical terms it is also acknowledged that there is a basic need for an appropriate wound dressing that will promote a moist wound healing environment, prepare the wound bed and prevent infection, all factors known to be important for progression of the wound healing process (Dowsett and Hall, 2019). It is therefore important that healthcare professionals delivering wound care are confident in the wound assessment process and in choosing a dressing that is going to promote wound healing and minimise the risk of wound complications.

KEY WORDS

NICE guidance

Nano-Oligosaccharide Factor (NOSF)

Wound care

UrgoStart Plus Treatment Range

JOY TICKLE

sTissue Viability Nurse Consultant Isle of Wight NHS Trust.